- Datum22.12.2025
- Uhrzeit17:00 - 19:00 Uhr
- Veranstalter
stock3
Cordula Lucas
Moderator
ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001 Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,31 %
Intraday
-0,98 %
1 Woche
-2,61 %
1 Monat
50,65 %
Seit Jahresbeginn
57,05 %
1 Jahr
-4,43 %
3 Jahre
-13,45 %
5 Jahre
2.925,98 %
10 Jahre
Passender Service zu ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Webinar zu ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)24,050-41,240
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Termine von ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
- Feb17ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001Q4 2025 Earnings Release
- Mai7ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001Q1 2026 Earnings Release
- Aug12ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001Q2 2026 Earnings Release
Beschreibung
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
